Agree. There are also markets for other lung diseases or complications of lung injury, COPD, sepsis etc.
Also agree that it would be nice to see readouts of 12 month secondary outcome measures such as pulmonary symptoms.
Let's hope@Bazsa 's intuition is right that this announcement may be preparing the market for a more substantial announcement including feed back from FDA in regards to the final potency assay. I thought this may be the case myself because the COVID ARDS trial will not commence until the potency assays (CMC) issues addressed.
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients, page-22
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |